Inflammatory Disease News and Research

RSS

Potential vaccine against trachoma

An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world's leading cause of infectious blindness, suggest findings from a National Institutes of Health study in monkeys.

10 Oct 2011

UNC researchers reveal genetic underpinnings of Foxp3-expressing regulatory T cells

Within the immune system, a subtle balance exists between the cells that destroy alien pathogens and those that preserve the body's own tissues. When the balance gets out of whack, the cells that normally target viruses or bacteria can go astray, attacking innocent cells and causing autoimmune and inflammatory disease.

20 Sep 2011

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

Novartis announced today positive results of the first pivotal Phase III trial of ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease. The results, presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, showed all primary and secondary endpoints of the study were met.

17 Sep 2011

Cam impingement may increase risk of hip OA in young men

Hip impingement may be a risk factor of osteoarthritis (OA) of the hip. A new study reveals that the presence of an underlying deformity, known as cam impingement, is associated with hip damage in young men without any arthritis symptoms and detected using magnetic resonance imaging.

8 Sep 2011

Scientists discover 29 new genetic variants linked with MS

Multiple sclerosis is primarily an immunological disease. Scientists at Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine (MDC) have in succeeded, in collaboration with 23 research teams from 15 different countries, in discovering a total of 29 new genetic variants that are involved in the genesis of multiple sclerosis (MS), an inflammatory disease of the nervous system.

7 Sep 2011

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

Chondroitin sulfate decreases pain and improves hand function in patients with OA

New research shows that chondroitin sulfate significantly decreased pain and improved hand function in patients with osteoarthritis (OA) of the hand compared with those in the placebo group. Results of the clinical trial available today in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), also report that chondroitin sulfate improves grip strength and relieves morning stiffness.

6 Sep 2011

Toclizumab for juvenile rheumatoid arthritis

The arthritis drug Toclizumab could be a boon for hundreds of children suffering from severe arthritis. It has been re-launched in children after being already licensed for the treatment of adults. At least two thirds of children taking tocizilumab have been able to return to a normal life, after many were bedridden or forced into wheelchairs by the disease, the clinical studies reveal.

16 Aug 2011

Starpharma starts bacterial vaginosis prevention study of VivaGel

Starpharma Holdings Limited today announced the commencement of its Phase 2 study of VivaGel for the prevention of bacterial vaginosis (BV), following receipt of ethics approval.

15 Aug 2011

Allergy & Asthma Specialists, P.C. adopts Aerocrine's FENO technology

Aerocrine AB today announced that Allergy & Asthma Specialists, P.C. has adopted Aerocrine's FENO technology for airway inflammation measurement as part of its clinical standardization on a system-wide basis.

12 Aug 2011

FDA accepts Teva's NDA for BDP Nasal HFA to treat allergic rhinitis

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

8 Aug 2011

Three new loci linked to asthma susceptibility in Japanese population

Researchers at the RIKEN Center for Genomic Medicine (CGM), together with colleagues at Kyoto University, Tsukuba University, Harvard University, and other medical institutions have identified three new loci associated with susceptibility to adult asthma in the Japanese population.

1 Aug 2011

New details about how dendritic cells regulate fate of naive T cells

St. Jude Children's Research Hospital scientists show that the molecule serves as a bridge between the two arms of the immune system that provides a new mechanism guiding T cell differentiation.

25 Jul 2011

Partners of Bacterial Vaginosis sufferers at increased risk of HIV

Starpharma Holdings Limited today commented on results of a study which showed that men were three times more likely to contract HIV from their female partners if the women also had bacterial vaginosis (BV) in the three months before the men became infected.

18 Jul 2011

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis.

18 Jul 2011

Sexually transmitted diseases more common in women age 40

A Johns Hopkins infectious disease expert is calling for all sexually active American women age 40 and older to get tested for the parasite Trichomonas vaginalis after new study evidence found that the sexually transmitted disease (STD) is more than twice as common in this age group than previously thought.

12 Jul 2011

Solution for treating obesity-related diseases may reside in fat tissue

Researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have shown that the quality – not just the quantity – of adipose, or fat, tissue is a significant contributing factor in the development of inflammation and vascular disease in obese individuals. The study, which is a special feature on the iPAD version of the Journal of the American College of Cardiology, provides compelling evidence that the answer to treating cardiovascular disease and other obesity-related disorders, such as type 2 diabetes and cancer, might be found in the adipose tissue itself.

7 Jul 2011